JAK-STAT Pathway Activation in Malignant and Non-Malignant Cells Contributes to MPN Pathogenesis and Therapeutic Response

The identification of JAK2/MPL mutations in patients with myeloproliferative neoplasms (MPN) led to the clinical development of JAK kinase inhibitors, including ruxolitinib. Ruxolitinib reduces splenomegaly and systemic symptoms in myelofibrosis (MF) and improves overall survival; however the mechan...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer Discov
Hauptverfasser: Kleppe, Maria, Kwak, Minsuk, Koppikar, Priya, Riester, Markus, Keller, Matthew, Bastian, Lennart, Hricik, Todd, Bhagwat, Neha, McKenney, Anna Sophia, Papalexi, Efthymia, Abdel-Wahab, Omar, Rampal, Raajit, Marubayashi, Sachie, Chen, Jonathan J., Romanet, Vincent, Fridman, Jordan S., Bromberg, Jacqueline, Teruya-Feldstein, Julie, Murakami, Masato, Radimerski, Thomas, Michor, Franziska, Fan, Rong, Levine, Ross L.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2015
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4355105/
https://ncbi.nlm.nih.gov/pubmed/25572172
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-14-0736
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge